Sam Brusco, Associate Editor03.11.23
Happy weekend, MPO readers! (Remember to turn your clocks forward an hour.)
Topping our readers' interest this week was a de novo approval granted to Neuromod Devices for its Lenire bimodal neuromodulation device to treat tinnitus (ringing in the ears). It's the first such device of its kind, according to the company. The runner-up this week was Abbott Lab's FDA clearance for its FreeStyle 2 and 3 integrated continuous glucose monitoring (iCGM) sensors to integrate with automated insulin devices. Taking bronze was my own article covering diabetes technologies in the recently released March 2023 edition of MPO.
Keep scrolling for links to this week's top stories!
5. New Agiliti CEO About to Assume Role
Topping our readers' interest this week was a de novo approval granted to Neuromod Devices for its Lenire bimodal neuromodulation device to treat tinnitus (ringing in the ears). It's the first such device of its kind, according to the company. The runner-up this week was Abbott Lab's FDA clearance for its FreeStyle 2 and 3 integrated continuous glucose monitoring (iCGM) sensors to integrate with automated insulin devices. Taking bronze was my own article covering diabetes technologies in the recently released March 2023 edition of MPO.
Keep scrolling for links to this week's top stories!